ArticleInternational journal of molecular sciences2026
Distinct Cytokine Profiles in Lupus Low Disease Activity State Subgroups Identify Patients at Risk for Disease Flare.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
We compared the cytokine profiles between two lupus low disease activity state (LLDAS) subgroups-clinically active (CA) and serologically active clinically quiescent (SACQ)-and identified predictors of disease flare. Fifty patients with systemic lupus erythematosus (25 CA, 25 SACQ) who maintained LLDAS for ≥6 months were enrolled and followed for 6 months. Cytokine modules were identified using weighted gene co-expression network analysis, and correlations with clinical traits were assessed. Predictors of flare were assessed using Cox regression. Three cytokine modules were identified. The brown (MCP-1 and IL-8) and turquoise (IFN-α, IFN-γ, IL-17A, IL-10, IL-12p70, IL-18, IL-23A, and IL-33) modules correlated with mucocutaneous and physician global assessment, respectively. These modules showed a positive, but not significant, correlation with CA. The comparison analysis revealed that IL-6 and IL-8 were higher in CA than in SACQ. Nine patients (18%) flared, six of whom belonged to the CA group. Flares were associated with a lower sustained LLDAS rate (77.8% vs. 34.1%) and higher levels of IL-1β, IL-6, and IL-33. In multivariable analysis, non-sustained LLDAS (HR 8.73) and IL-6 ≥ 45.1 pg/mL (HR 10.4) independently predicted a flare. Our study demonstrated that cytokine elevation persists despite LLDAS. Non-sustained LLDAS and elevated IL-6 predict a flare, suggesting that IL-6 may enhance the flare prediction biomarker.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.